New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 20, 2014
11:09 EDTTWGP, CMLP, HAIN, BXE, FOLD, NM, CIG, FCS, CODE, INFIHigh option volume stocks
High option volume stocks: TWGP CODE FCS CIG NM FOLD BXE HAIN CMLP INFI
News For TWGP;CODE;FCS;CIG;NM;FOLD;BXE;HAIN;CMLP;INFI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 28, 2014
14:10 EDTFOLDGlaxoSmithKline liquidates passive stake in Amicus Therapeutics
Subscribe for More Information
09:37 EDTFOLDActive equity options trading
Subscribe for More Information
08:59 EDTFOLDAmicus Therapeutics 11.32M share Block Trade priced at $5.40
Subscribe for More Information
October 27, 2014
08:06 EDTCMLPCrestwood constructs additional release, departure rails at COLT Hub
Subscribe for More Information
October 22, 2014
10:18 EDTHAINBoulder Brands tumbles after lowering profit outlook
Subscribe for More Information
October 20, 2014
14:29 EDTCODEEarnings Preview: Texas Instruments down 9% over last three months
Semiconductor maker Texas Instruments (TXN) is expected to report third quarter earnings after the close on Monday, October 20, with a conference call scheduled for 5:30 pm ET. EXPECTATIONS: Analysts are looking for earnings per share of 71c on revenue of $3.46B. The consensus range is 66c-74c for EPS on revenue of $3.44B-$3.5B, according to First Call. Along with its last earnings report, Texas Instruments guided to Q3 EPS of 66c-76c on revenue of $3.31B-$3.59B. LAST QUARTER: On July 21, Texas Instruments reported second quarter EPS of 62c, which was higher than analysts' consensus of 59c. The company's revenue of $3.29B exceeded analysts' expectation of $3.27B. Texas Instruments noted that the restructuring changes which occurred in Q2 are positioned to be nil in Q3 and noted that it anticipated utilization in Q3 to remain consistent with Q2 levels. NEWS: On September 18, Texas Instruments increased its quarterly dividend by 13% to 34c. WHAT'S NOTABLE: After the close on October 9, Microchip (MCHP), which develops microcontroller and analog semiconductors, said that it had experienced a number of negative trends during the quarter, including a weaker than usual September, weakness in China, and significant inventory builds at its distributor customers. Microchip President and CEO Steve Sanghi claimed his company often sees the turn of the semiconductor industry ahead of others, noting that it reports sales from distribution on a sell-through basis and that it does business with over 80,000 customers. Sanghi stated, "We believe that another industry correction has begun and that this correction will be seen more broadly across the industry in the near future." STREET RESEARCH: Analysts were fairly quiet on Texas Instruments during the quarter. The day after the company issued its Q2 earnings report, Sterne Agee believed that Texas Instruments' commentary on 4G telecom, auto and industrial strength should be positive for Spansion (CODE). RBC Capital noted on the same day that Texas Instruments had "strong" Q2 results, particularly in its execution, while its operating margin leverage was "impressive. The firm maintained a $57 price target and Outperform rating on the stock. On July 24, Tigress Financial upgraded Texas Instruments to Neutral from Underperform. PRICE ACTION: Over the last three months, Texas Instruments' shares are down about 9%. Since October 10, the day after Microchip's warning on the industry correction it believes has begun, Texas Instruments shares are down over 3%. In afternoon trading before tonight's report, Texas Instruments was up 1.7% to $44.41.
07:10 EDTFOLDAmerican Society of Human Genetics to hold annual meeting
Subscribe for More Information
07:04 EDTINFIInfinity Pharmaceuticals coverage resumed with a Hold at Stifel
October 19, 2014
19:46 EDTFOLDAmicus announces additional positive data from from Fabry monotherapy study
Subscribe for More Information
October 16, 2014
11:36 EDTCODEOptions with increasing implied volatility
Options with increasing implied volatility: UVXY NQ PVA SVXY VXX SUNE CIE COV ZU CODE
07:41 EDTFCSFairchild sees Q4 revenue $340M-$360M, consensus 367.53M
Fairchild CFO Mark Frey stated, "We expect sales to be in the range of $340M-$360M for Q4. We expect adjusted gross margin to be 33%-34% due primarily to lower sales and the impact of reduced factory loadings in the prior quarter. We anticipate R&D and SG&A spending to be $95M-$97M. The adjusted tax rate is forecast at 12% plus or minus 3 percentage points for the quarter. Consistent with our usual practices, we are not assuming any obligation to update this information, although we may choose to do so before we announce Q4 results."
07:41 EDTINFIInfinity reports duvelisib Phase 2a primary endpoint not met
Infinity Pharmaceuticals announced encouraging topline data from its Phase 2a exploratory study of duvelisib, or IPI-145. Data from this randomized, double-blind, placebo-controlled, cross-over study demonstrated that duvelisib was well tolerated and met several secondary and exploratory endpoints in an allergen challenge study. Clinical improvement was observed in the late-phase asthmatic response FEV1 among patients who received duvelisib administered at the highest dose tested, 25 mg twice daily for five days, however the primary endpoint of the study was not met as it did not reach statistical significance. Multiple secondary clinical endpoints measuring improvements in lung function following duvelisib administration were achieved with statistical significance and were associated with changes in key cytokines and chemokines involved in the asthmatic response. Taken together, these data demonstrate early proof-of-activity in this allergen challenge study. Infinity expects to present the final data in a peer-reviewed setting after all analyses are complete. In addition, the company anticipates determining its next steps for development of PI3K-delta,gamma inhibitors in inflammation after evaluating the results from the ASPIRA study in rheumatoid arthritis, which are expected by the end of 2014.
07:39 EDTFCSFairchild reports Q3 adjusted EPS 28c, consensus 21c
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use